Wait a second!
More handpicked essays just for you.
More handpicked essays just for you.
Gene patenting views essay
Essaya About The Human Genome Project
Essaya About The Human Genome Project
Don’t take our word for it - see why 10 million students trust us with their essay needs.
Recommended: Gene patenting views essay
In June 2000, the publicly funded Human Genome Project (HGP) and the private firm Celera Genomics Inc. announced that they had completed sequencing the human genome. This unprecedented accomplishment is expected to enable doctors to diagnose, treat and even prevent numerous genetic diseases. As these two entities worked on sequencing the human genome, there was also a separate and less publicized race to patent as many human genes as possible.
The patenting issue gained some attention when President Bill Clinton and Prime Minster Tony Blair jointly called for the release of raw genetic data into the public domain (CQ 405). I will argue in this paper that the aggressive competition among biotechnology firms to patent genes is impeding development being made in biomedical sector. The main problem with patenting genes is that companies are filing patents for strands of DNA they discover without fully knowing their functions (Kluger 51). The current attitude in the biotechnology sector seems to be, to gain exclusive access to as much of the human genome as possible first and then figure out the functions of the genes later. Despite the questionable attitude in the biotechnology sector, the current patent laws are allowing companies to continue with their practices. The patents laws are not able to deal with new complications that arise of from patenting genes. As I will argue in this paper, there is a pressing need to modify these laws to permit the HGP and its consequences to benefit everyone rather than lining the pockets of few corporations.
Patents have always represented a mutually beneficial a relationship between inventor and public. The inventor gets 17 years of basic monopoly on his invention so that he ...
... middle of paper ...
...while not impeding progress in bio-medical technology.
Works Cited
Bethell, Tom, Boastful Genome Science, The American Spectator v.33 no 7 (Sept 2000)
Bobrow, Martin, Patents in a Genetic Age, Nature (Feb 15, 2001)
Doll, John, Talking Gene Patents, Scientific American (August 2000)
Hildyard, Nicholas., No Patents on Life, Forum for Applied Research and Public Policy v 15 (Spring 2000)
Kaiser, Jocelyn, Renewed Fight Over Gene Patent Policy, (April 11, 1997) Kluger, Jeffery, Who Owns Our Genes, Time. (Jan 11, 1999)
Regalado, Antonio, The Great Gene Grab, Technology Review, Cambridge Mass. 1998 v 103 Sept/Oct 2000
Shulman, Seth, Toward Sharing the Genome, Technology Review, v.103 (Sept/Oct 2000)
A Double Edged Sword, Canada and the World Backgrounder v66 (Oct 2000) Human Genome Project (2000), Congressional Quarterly
(7) Hall B. Patents and Patent Policy -. 2007. The 'Secondary' of the 'Secondary' of the 'Secondary' of the 'Secondary' of the 'Secondary' of the 'Secondary' of the 'Secondary' of the Morse H. SETTLEMENT OF INTELLECTUAL PROPERTY DISPUTES IN THE PHARMACEUTICAL AND MEDICAL DEVICE INDUSTRIES: ANTITRUST RULES. Allison JR, Lemley MA, Moore KA, Trunkey RD. Valuable patents. Geol.
The PBS documentary “Nova – Cracking Your Genetic Code” tells about the genome sequencing technology: its current possibilities, advantages, disadvantages and future potential. The system became cheaper, faster and more available since the first human genome was fully sequenced in 2000. Modern companies use the technology to provide clients with the information about their genes and impacts they can have on owners’ health. Hospitals can provide more accurate diagnosis and personalized treatments with the aid of the genome sequencing. The video shows several examples of these benefits. But it mentions concerns about the quality of services, risks of exaggerated
In the late twentieth century, the field of biotechnology and genetic engineering has positioned itself to become one of the great technological revolutions of human history. Yet, things changed when Herber Boyer, a biochemist at the University of California, founded the company Genentech in 1976 to exploit the commercial potential of his research. Since then the field has exploded into a global amalgam of private research firms developing frivolous, profit-hungry products, such as square trees tailor-made for lumber, without any sort of government regulation.
The more we know about genetics and the building blocks of life the closer we get to being capable of cloning a human. The study of chromosomes and DNA strains has been going on for years. In 1990, the Unites States Government founded the Human Genome Project (HGP). This program was to research and study the estimated 80,000 human genes and determine the sequences of 3 billion DNA molecules. Knowing and being able to examine each sequence could change how humans respond to diseases, viruses, and toxins common to everyday life. With the technology of today the HGP expects to have a blueprint of all human DNA sequences by the spring of 2000. This accomplishment, even though not cloning, presents other new issues for individuals and society. For this reason the Ethical, Legal, and Social Implications (ELSI) was brought in to identify and address these issues. They operate to secure the individuals rights to those who contribute DNA samples for studies. The ELSI, being the biggest bioethics program, has to decide on important factors when an individual’s personal DNA is calculated. Such factors would include; who would have access to the information, who controls and protects the information and when to use it? Along with these concerns, the ESLI tries to prepare for the estimated impacts that genetic advances could be responsible for in the near future. The availability of such information is becoming to broad and one needs to be concerned where society is going with it.
Watson, James D. "The Human Genome Project: A Personal View." Writing and Reading Across the Curriculum. 7th ed. Ed.
So what is a human genome and why is the government researching it? The Human genome is the sequence of roughly 20,000 genes that make up human Deoxyribonucleic acid (DNA), or the building blocks that tell cells what to do. The government project named Human Genome Project (HGP) started in 1990’s, and is trying to unravel the 3 billion chemical base pairs in a DNA strand (http://www.ama-assn.org/ama/pub/physician-resources/medical-science/genetics-molecular-medicine/current-topics/human-genome.shtml.)
Outsourcing has only very recently become an issue in the United States, and as a result it has become a very popular political issue during campaigns for presidency. Outsourcing is the idea that a company will subcontract to a third party, usually outside of the US, for various parts of its business structure. An example of this and perhaps the largest source of outsourcing is call centers for tech support, where a company will subcontract to a third party and that party will build up the call center and hire the workers for it. Many people have been affected by outsourcing since it started being used widely in the 1980s, and most would argue that outsourcing is not a good business model, that while it not only negatively affects them, it affects the whole economy. While there are some unmistakable positives to outsourcing, I would argue that as a whole, the negatives far outweigh the positives and outsourcing is bad for the United States.
For several decades, patents have been issued for the genes of various life forms including plants, animals, and segments of human DNA. Typically, gene patent holders are researchers in federal organizations, colleges, and companies; they often collect patents as a means for protecting their investment in research. The U.S. Patent and Trademark Office allows for genes to be protected as intellectual property with the intention of encouraging research and innovation, just as with any patent. However, gene patents have proliferated while leaving fundamental questions unanswered: do gene patents truly nourish innovation as other patents do, and what are their implications on society and on the lifeforms whose genes are subject to patenting? With further investigation, their negative impact will become apparent.
Not all genes are the same, in fact, some human genetics are remarkable. So much so, that we have instituted research into our lives. The timeline presented by Kenneth Jost of the CQ Researcher suggests we have been discovering and patenting specific genetic discoveries since 1911 with the first patenting being the discovery of adrenaline and reproduction of the cells for the general public. Although we share different genes within our species, there are so many separate genetic markers that create our specific identity as humans. Within the research, we are also finding cures to cancers and diseases that have been due to the genetic research. Biotech companies have creating vaccines and medicine with these genetic discoveries. Shouldn’t they be entitled to patenting their discovery and product? Why would there be a problem with patenting these markers discovered for cures?
The case study of the Frigidaire Corporation illustrates that valuable data has been collected; therefore, if applied correctly, the company has the potential to position the new front-loading washing machine in the correct market segment(s). According to Exhibit 5 in the case study, the following populations have above concern for conservation of resources: Elite urban singles between the ages of 25 and 34 and couples between the ages of 35 and 54 both of value space savings; Sophisticated townhouse White and Asian couples who are 55 years old or older have above average ecological concerns; Upscale suburban Asian and White families between the ages of 35 and 54 have determinant attributes of performance ...
Unilever is the world third largest consumer goods company which produces a wide range of foods, home care and personal care products. Behind the sustained development over 8...
From a long term perspective, Unilever should try to streamline its management system, at the same time; there may be another program works as a fast track of delivering a product so Unilever won’t miss short trend of consumption. “A structured approach to decision-making could need to maintain a dual internal and external focus to prevent important opportunities and threats from being overlooked (Palisade, 2014).” The overall management efficiency should be measured by the length of design a new line of products to the official launch of the product to distribution channels.
... between firm IT capability collaboration and performance',[online] Journal of Business Logistics, Oak Brook: volume 26,Iss.1, pg 1-24, [Accessed 10 26 2005].
Outsourcing is a subject in which there is a lot to analyze a talk about. There is many issues which are currently in the air and which are still being debated and will probably be debated for the next few years. What we conclude based on these presented issues is that everything will always have negatives and positives. I think that America should closely look and try to figure something out that will satisfy its own people and not just leave as it is. They should realize that not having enough jobs, or keep making loose jobs is not un answer. It looks like it might be getting worse and worse.
As the construction industry globalises and regional boundaries become less relevant, the survival of a construction firm will increasingly be determined by its ability to create and sustain a strong internet marketing strategy. The majority of the companies operating in the market are small and locally based. In 1998, the Construction Task Force reported that the industry was suffering from low levels of productivity and re-investment, but in subsequent years, marked by historically low interest rates, growth has greatly improved. The UK construction and engineering market reached a value of £19.3 billion in 2002, giving an overall growth of 0.6% since 1998, outperforming the European average. The UK market share at the end of 2002 was 14.3%, giving it the second largest share of the European market. In Scotland in particular, the construction industry has outperformed the UK average for new construction contracts with a 25.3% increase from 2001 to 2003, worth £3.4 billion.